Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: A propensity score analysis

Clinical Infectious Diseases

Volumn 58, Issue 10, 2014, Pages 1413-1421

  Fernández Ruiz, Mario ^a   Aguado, José María ^a   Almirante, Benito ^b,c   Lora Pablos, David ^a   Padilla, Belén ^d   Puig Asensio, Mireia ^b,c   Montejo, Miguel ^e   García Rodríguez, Julio ^f   Pemán, Javier ^g   De Pipaón, Maite Ruiz Pérez ^h   Cuenca Estrella, Manuel ⁱ  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e HOSPITAL DE CRUCES   (Spain)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^g HOSPITAL UNIVERSITARIO LA FE   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

ⁱ INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Bloodstream infection; Candida parapsilosis; Echinocandin; Propensity score; Treatment

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; VORICONAZOLE; ANTIFUNGAL AGENT;

ADULT; ANTIFUNGAL SUSCEPTIBILITY; ANTIMICROBIAL THERAPY; ARTICLE; BLOODSTREAM INFECTION; CANDIDA PARAPSILOSIS; CANDIDEMIA; CENTRAL VENOUS CATHETER; DISEASE SURVEILLANCE; DNA SEQUENCE; DRUG USE; ENDOTRACHEAL INTUBATION; FEMALE; FOLLOW UP; HUMAN; INTENSIVE CARE UNIT; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPTIC SHOCK; SPECIES; TREATMENT OUTCOME; AGED; ANTIFUNGAL RESISTANCE; CANDIDA; CLINICAL TRIAL; DRUG EFFECTS; HEALTH SURVEY; INFANT; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PROPENSITY SCORE; RISK FACTOR; SPAIN;

ADULT; AGED; ANTIFUNGAL AGENTS; CANDIDA; CANDIDEMIA; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FEMALE; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; POPULATION SURVEILLANCE; PROPENSITY SCORE; PROSPECTIVE STUDIES; RISK FACTORS; SEQUENCE ANALYSIS, DNA; SPAIN; TREATMENT OUTCOME;

EID: 84899890873     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu158     Document Type: Article

References (40)

1. Almirante B, Rodríguez D, Park BJ, et al. Epidemiology and predictorsof mortality in cases of Candida bloodstream infection: results frompopulation-based surveillance, Barcelona, Spain, from 2002 to 2003. JClin Microbiol 2005; 43:1829-35.
2. Cisterna R, Ezpeleta G, Telleria O; Spanish Candidemia SurveillanceGroup. Nationwide sentinel surveillance of bloodstream Candida infectionsin 40 tertiary care hospitals in Spain. J Clin Microbiol 2010;48:4200-6.
3. Tortorano AM, Biraghi E, Astolfi A, et al. European Confederation ofMedical Mycology (ECMM) prospective survey of candidaemia: reportfrom one Italian region. J Hosp Infect 2002; 51:297-304.
4. Rennert G, Rennert HS, Pitlik S, Finkelstein R, Kitzes-Cohen R. Epidemiologyof candidemia-a nationwide survey in Israel. Infection 2000;28:26-9.
5. Nucci M, Queiroz-Telles F, Alvarado-Matute T, et al. Epidemiology ofcandidemia in Latin America: a laboratory-based survey. PLoS One2013; 8:e59373.
6. Almirante B, Rodríguez D, Cuenca-Estrella M, et al. Epidemiology, riskfactors, and prognosis of Candida parapsilosis bloodstream infections:case-control population-based surveillance study of patients in Barcelona,Spain, from 2002 to 2003. J Clin Microbiol 2006; 44:1681-5.
7. MacCallum DM. Hosting infection: experimental models to assay Candidavirulence. Int J Microbiol 2012; 2012:363764.
8. Silva S, Negri M, Henriques M, Oliveira R, Williams DW, Azeredo J.Adherence and biofilm formation of non-Candida albicans Candidaspecies. Trends Microbiol 2011; 19:241-7.
9. Pammi M, Holland L, Butler G, Gacser A, Bliss JM. Candida parapsilosisis a significant neonatal pathogen: a systematic review and metaanalysis.Pediatr Infect Dis J 2013; 32:e206-16.
10. Garcia-Effron G, Katiyar SK, Park S, Edlind TD, Perlin DS. A naturallyoccurring proline-to-alanine amino acid change in Fks1p in Candidaparapsilosis, Candida orthopsilosis, and Candida metapsilosis accountsfor reduced echinocandin susceptibility. Antimicrob Agents Chemother2008; 52:2305-12.
11. Pfaller MA, Diekema DJ, Andes D, et al. Clinical breakpoints for theechinocandins and Candida revisited: integration of molecular, clinical,and microbiological data to arrive at species-specific interpretive criteria.Drug Resist Updat 2011; 14:164-76.
12. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofunginand amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-9.
13. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazolefor invasive candidiasis. N Engl J Med 2007; 356:2472-82.
14. Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomalamphotericin B for candidaemia and invasive candidosis: a phaseIII randomised double-blind trial. Lancet 2007; 369:1519-27.
15. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofunginfor treatment of candidemia and other forms of invasive candidiasis.Clin Infect Dis 2007; 45:883-93.
16. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelinesfor the management of candidiasis: 2009 update by the Infectious DiseasesSociety of America. Clin Infect Dis 2009; 48:503-35.
17. Cornely OA, Bassetti M, Calandra T, et al. ESCMID* guideline for thediagnosis and management of Candida diseases 2012: non-neutropenicadult patients. Clin Microbiol Infect 2012; 18(suppl 7):19-37.
18. Pfaller MA, Diekema DJ, Gibbs DL, et al. Geographic and temporaltrends in isolation and antifungal susceptibility of Candida parapsilosis:a global assessment from the ARTEMIS DISK Antifungal SurveillanceProgram, 2001 to 2005. J Clin Microbiol 2008; 46:842-9.
19. Gonçalves SS, Amorim CS, Nucci M, et al. Prevalence rates and antifungalsusceptibility profiles of the Candida parapsilosis species complex:results from a nationwide surveillance of candidaemia in Brazil. ClinMicrobiol Infect 2010; 16:885-7.
20. Cantón E, Pemán J, Quindós G, et al. Prospective multicenter study ofthe epidemiology, molecular identification, and antifungal susceptibilityof Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosisisolated from patients with candidemia. Antimicrob Agents Chemother2011; 55:5590-6.
21. Garcia-Effron G, Canton E, Pemán J, Dilger A, Romá E, Perlin DS. Epidemiologyand echinocandin susceptibility of Candida parapsilosissensu lato species isolated from bloodstream infections at a Spanish universityhospital. J Antimicrob Chemother 2012; 67:2739-48.
22. Arendrup MC, Rodriguez-Tudela JL, Lass-Flörl C, et al. EUCAST technicalnote on anidulafungin. Clin Microbiol Infect 2011; 17:E18-20.
23. Kett DH, Shorr AF, Reboli AC, Reisman AL, Biswas P, Schlamm HT.Anidulafungin compared with fluconazole in severely ill patients withcandidemia and other forms of invasive candidiasis: support for the2009 IDSA treatment guidelines for candidiasis. Crit Care 2011; 15:R253.
24. Andes DR, Safdar N, Baddley JW, et al. Impact of treatment strategy onoutcomes in patients with candidemia and other forms of invasive candidiasis:a patient-level quantitative review of randomized trials. ClinInfect Dis 2012; 54:1110-22.
25. Puig-Asensio M, Padilla B, Garnacho-Montero J, et al. Epidemiologyand predictive factors for early and late mortality in Candida bloodstreaminfections: a population-based surveillance in Spain. Clin MicrobiolInfect 2014; 20:O245-54.
26. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for thediagnosis and management of intravascular catheter-related infection:2009 update by the Infectious Diseases Society of America. Clin InfectDis 2009; 49:1-45.
27. Paterson DL, Ko WC, Von Gottberg A, et al. Antibiotic therapy forKlebsiella pneumoniae bacteraemia: implications of production of extended-spectrum β;-lactamases. Clin Infect Dis 2004; 39:31-7.
28. Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapyand study outcomes in clinical trials of invasive fungal diseases: MycosesStudy Group and European Organization for Research and Treatmentof Cancer consensus criteria. Clin Infect Dis 2008; 47:674-83.
29. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMIDEuropean Committee for Antimicrobial Susceptibility Testing(EUCAST). EUCAST definitive document EDef 7.1: method for the determinationof broth dilution MICs of antifungal agents for fermentativeyeasts. Clin Microbiol Infect 2008; 14:398-405.
30. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope W; EUCASTAFST.EUCAST technical note on the EUCAST definitive documentEDef 7.2: method for the determination of broth dilution minimuminhibitory concentrations of antifungal agents for yeasts EDef 7.2(EUCAST-AFST). Clin Microbiol Infect 2012; 18:E246-7.
31. European Committee on Antimicrobial Susceptibility Testing(EUCAST). Antifungal agents. Breakpoint tables for interpretation ofMICs (version 6.1). Available at: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/AFST/ Antifungal-breakpoints-v-6.
32. Austin PC. An introduction to propensity score methods for reducingthe effects of confounding in observational studies. Multivariate BehavRes 2011; 46:399-424.
33. Austin PC. The performance of different propensity score methods forestimating marginal odds ratios. Stat Med 2007; 26:3078-94.
34. Fortún J, Martín-Dávila P, Gómez- García de la Pedrosa E, et al. Emergingtrends in candidemia: a higher incidence but a similar outcome. JInfect 2012; 65:64-70.
35. Pfaller M, Neofytos D, Diekema D, et al. Epidemiology and outcomes ofcandidemia in 3648 patients: data from the Prospective AntifungalTherapy (PATH Alliance) registry, 2004-2008. Diagn Microbiol InfectDis 2012; 74:323-31.
36. Tortorano AM, Prigitano A, Lazzarini C, et al. A 1-year prospective surveyof candidemia in Italy and changing epidemiology over one decade.Infection 2013; 41:655-62.
37. Girmenia C, Martino P, De Bernardis F, et al. Rising incidence of Candidaparapsilosis fungemia in patients with hematologic malignancies:clinical aspects, predisposing factors, and differential pathogenicity ofthe causative strains. Clin Infect Dis 1996; 23:506-14.
38. Miranda LD, Rodrigues EC, Costa SF, et al. Candida parapsilosis candidaemiain a neonatal unit over 7 years: a case series study. BMJ Open2012; 2. doi:10.1136/bmjopen-2012000992.
39. Rodriguez D, Park BJ, Almirante B, et al. Impact of early central venouscatheter removal on outcome in patients with candidaemia. Clin MicrobiolInfect 2007; 13:788-93.
40. Nucci M, Anaissie E, Betts RF, et al. Early removal of central venouscatheter in patients with candidemia does not improve outcome: analysisof 842 patients from 2 randomized clinical trials. Clin Infect Dis2010; 51:295-303.